Healthcare entity
market-trends is the sole category represented across all 2 tracked stories. Bayer is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 6.5 original sources each against 3.3 for the same window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 2 tracked stories. Bayer is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. They are better corroborated than the beat average, carrying 6.5 original sources each against 3.3 for the same window. The 7 average consequence score is above the beat benchmark of 6.6 in the same window. HMI-115 appears in 2 tracked Healthcare stories from March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering HMI-115. Shared-story counts are live from our verified record — not editorial picks.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.
Source: manilatimes.net · prnewswire.com
HMI-115 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
